Analysis of TCGA-LUAD data revealed that elevated IGF2BP3 expression correlates with advanced tumor stages and poor patient survival, consistent with its established role in stabilizing pro-survival transcripts such as c-MYC and CD44 (Palanichamy et al., 2016; Liu et al., 2017). This evidence concerns the gene IGF2BP3 and neoplasm.